Investigational drug · Phase 2
MHB036C
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Breast Cancer, Advanced Malignant Solid Tumor, Advanced Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "MHB036C"
First trial start
2023
May 26, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MHB036C", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Breast Cancer
- Advanced Malignant Solid Tumor
- Advanced Lung Cancer
- Advanced Solid Tumor
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MHB036C" as an intervention, largest first.
- Study of MHB036C in Participants With Advanced or Metastatic Solid TumorsPivotal-lookingStatus unknown
Minghui Pharmaceutical Pty LtdIndustry
NCT05642949 · 400 participants (planned) · Start Jan 23, 2023 · Primary completion Dec 31, 2025
Drug: MHB036C · For: Advanced Solid Tumor
Sites: Gold Coast, Australia; Adelaide, Australia; Melbourne, Australia
- A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung CancerRecruiting
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07229599 · 300 participants (planned) · Start May 9, 2025 · Primary completion May 2029
Drug: MHB036C for Injection; MHB039A for Injection and 2 more · For: Advanced Lung Cancer
Sites: Shanghai, China
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT07130383 · 210 participants (planned) · Start Sep 30, 2025 · Primary completion Aug 2029
Drug: MHB036C for Injection; MHB039A for Injection · For: Advanced Breast Cancer; Advanced Malignant Solid Tumor
Sites: Shanghai, China
- A Study of MHB036C for Advanced Solid TumorActive, not recruiting
Minghui Pharmaceutical (Hangzhou) LtdIndustry
NCT06373406 · 200 participants (planned) · Start May 26, 2023 · Primary completion Apr 2027
Drug: MHB036C · For: Advanced Solid Tumor
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Breast Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- UtidelonePhase 38 trials
Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma
- KN026PlacboPhase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Advanced Breast Cancer, Resectable HER2-positive Breast Cancer
- PalazestrantOP-1250Phase 32 trials
Olema Oncology, Inc. · Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
- RYZ101Phase 32 trials
RayzeBio, Inc. · Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer
- XZP-3287Phase 32 trials
Xuanzhu Biopharmaceutical Co., Ltd. · Advanced Breast Cancer
- ZovegalisibPhase 31 trial
Relay Therapeutics, Inc. · PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor
- MHB039APhase 24 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.